Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Vitamin E Supplements Linked to Increased Risk of Prostate Cancer

October 12th 2011

Vitamin E may increase the risk of developing prostate cancer in men who have taken the supplement for 5 years or longer.

Pharmaceutical Company Profile: Dendreon Corporation

October 4th 2011

Dendreon estimates that only about 25% of eligible prescribing physicians were aware that Medicare had decided to cover Provenge for its on-label use of treating prostate cancer.

Survival Benefit Shown With Investigational Alpha-Emitting Radiopharmaceutical in Men With Hormone Resistant Metastatic Prostate Cancer

September 24th 2011

Investigational drug that emits alpha radiation shows significant improvement in overall survival.

Two Predictors of Prostate Cancer Explored in Healthy Men

September 23rd 2011

Two studies enhance understanding of risk factors for prostate cancer.

Value-Based Coverage Decisions: CMS Scrutinizes Provenge

August 25th 2011

In late March, CMS ended the speculation by announcing its intention to pay for onlabel uses of the drug, which costs $93,000 for a 3-dose regimen, while leaving off-label coverage decisions to its regional contractors.

ASCO Highlights: Trials in Progress

August 23rd 2011

The following is a roundup of TPS abstracts that feature trials open to patients aged >17 years with a broad range of cancer types.

Cost/Benefit Ratio of Denosumab Is Questionable When Treating Patients With Metastatic CRPC

July 29th 2011

The use of denosumab to prevent SREs in men with mCRPC has questionable cost-effectiveness as compared with zoledronic acid.

Amgen Seeks to Expand Xgeva's FDA Approval

July 11th 2011

A pivotal phase III study found that men with CRPC experienced prolonged bone metastasisâ€“free survival with Xgeva versus placebo.

Acetaminophen Use May Cut Risk of Prostate Cancer

July 6th 2011

New findings suggest that long-term, regular acetaminophen use may be associated with a lower risk of prostate cancer.

Dr. Scher on Using the Circulating Tumor Cells Test

June 30th 2011

Dr. Howard Scher from MSKCC on Using the Circulating Tumor Cells Test

Dr. Vogelzang Discusses Cabozantinib's Dose Size

June 29th 2011

Dr. NJ Vogelzang from the Comprehensive Cancer Centers of Nevada Discusses Cabozantinib's Dose Size

Dr. Scher on the Future of the Circulating Tumor Cell Test

June 28th 2011

Dr. Howard Scher from Memorial Sloan-Kettering on the Future of the Circulating Tumor Cell Test

Donna Berry on Prostate Cancer Patients' Challenges

June 28th 2011

Donna Berry on the Challenges Patients With Prostate Cancer Face

Dr. Scher on Circulating Tumor Cells in Prostate Cancer

June 27th 2011

Dr. Howard Scher from Memorial Sloan-Kettering on Circulating Tumor Cells in Prostate Cancer

FDA Roundup, Including Latest on Avastin Hearing

June 24th 2011

The FDA recently approved a new drug formulation, mandated label changes for cigarettes and sunscreens, and issued an opinion on breast implants.

Dr. Scher Discusses Circulating Tumor Cells

June 23rd 2011

Dr. Howard Scher form Memorial Sloan-Kettering Cancer Center Discusses Circulating Tumor Cells

Dr. Vogelzang Describes Cabozantinib's Side Effects

June 21st 2011

Dr. Nicholas Vogelzang from the Comprehensive Cancer Centers of Nevada Describes Cabozantinib's side effects

Dr. Vogelzang on Cabozantinib Clinical Trial Results

June 20th 2011

Dr. Nicholas J. Vogelzang from the Comprehensive Cancer Centers of Nevada on Cabozantinib Clinical Trial Results

Digoxin Found to Be Effective in the Fight Against Prostate Cancer

June 17th 2011

A search for potential chemopreventive agents for prostate cancer uncovered an unlikely candidate in digoxin, one of the oldest drugs for cardiovascular disorders

Novel Hormone-Radiation Therapy Approaches

June 11th 2011

Radiation therapy (RT) used in combination with hormonal approaches continues to be a viable strategy for treating localized, high-risk prostate cancer patients